Data completeness
0/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COACTIN is a Roche-sponsored small-molecule injectable in pre-launch phase with an approved NDA. Mechanism of action, indication(s), and patient population remain undisclosed. This drug represents a pipeline asset transitioning toward market entry.
Pre-Launch
Pre-launch products generate recruitment across commercial, medical, and operations teams; team expansion likely in 12–18 months pre-approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COACTIN is a pre-launch asset with zero identified open positions at present, but career opportunities will accelerate significantly as approval nears. Working on a Roche injectable in early commercial phase provides exposure to launch strategy, payer negotiation, and market infrastructure build.
Brand ManagerProduct Manager
Worked on COACTIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.